Jacquelyn J. Maher, MD

Jacquelyn J. Maher, MD

Professor, Department of Medicine, UCSF


Phone: (415) 206-4810 (voice)
SFGH, Bldg. 40, 4102, San Francisco, CA 94143

View on UCSF Profiles

Cancer Center Membership

Associate Member ยป Non-aligned

Research Summary


BA: Duke University

MD: Duke University School of Medicine

Residency: Duke University Medical Center, Internal Medicine

Fellowship: University of California, San Francisco, Gastroenterology




Dr. Maher is Chief of the Division of Gastroenterology at San Francisco General Hospital and Director of the UCSF Liver Center. Research in her laboratory focuses on the pathogenesis of fatty liver disease. Special emphasis is placed on the effects of individual dietary macronutrients on liver injury. Her studies in mice implicate dietary sugar as an important inducer of fatty liver disease, through conversion to toxic saturated fatty acids. Ongoing work in her group concentrates on the synergistic toxicity of dietary sugar and saturated fat. Experiments also focus on the mechanism by which saturated fatty acids kill liver cells.


Duke University, BA, 1972-1976, Chemistry
Duke University Medical Center, MD, 1976-1979
Duke University Medical Center, 1/1980-6/1980, Research Fellowship, Hematology
Duke University Medical Center, 1980-1983, Internal Medicine Residency
University of California, San Francisco, 1983-1984, Clinical Fellowship, GI
University of California, San Francisco, 1984-1987, Research Fellowship, GI

Professional Experience

  • Jan-June, 1980
    Research Fellow in Hematology, Duke University Med. Ctr. (W. F. Rosse, preceptor)
  • July 1980-1983
    Resident in Internal Medicine, Duke University Medical Center
  • July 1983-1984
    Clinical Fellow in Gastroenterology, University of California, San Francisco
  • July 1984-1987
    Research Fellow in Gastroenterology, University of California, San Francisco (D. Montgomery Bissell and F. Joseph Roll, preceptors)
  • July 1987-1995
    Assistant Professor of Medicine, University of California, San Francisco
  • July 1995-2003
    Associate Professor of Medicine, University of California, San Francisco
  • July 2003-present
    Professor of Medicine, University of California, San Francisco
  • July 1997-present
    Director, Rice Liver Center Laboratory, San Francisco General Hospital
  • Jun 1998-Jan 2001
    Interim Chief of Gastroenterology, San Francisco General Hospital

Honors & Awards

  • 1975
    Phi Beta Kappa, Duke University
  • 1982-83
    Assistant Chief Resident in Medicine, Duke University Medical Center
  • 1985-86
    American Liver Foundation Postdoctoral Research Fellowship
  • 1986-87
    American Gastroenterological Association Research Fellowship
  • 1989-90
    Faculty Development Award, UCSF
  • 1994-96
    Alcoholic Beverage Medical Research Foundation Award
  • 1996
    Member of NIAAA Research Delegation on Alcoholic Liver Disease, Mexico
  • 1996-01
    Research Scientist Development Award, NIAAA
  • 1996-01
    Associate Editor, Hepatology
  • 1997-02
    Editorial Board, American Journal of Physiology
  • 2001-05
    Editorial Board, Hepatology

Selected Publications

  1. Differential hepatotoxicity of dietary and DNL-derived palmitate in the methionine-choline-deficient model of steatohepatitis. BMC Gastroenterol. 2015; 15:72.
    View on PubMed
  2. A screen in mice uncovers repression of lipoprotein lipase by microRNA-29a as a mechanism for lipid distribution away from the liver. Hepatology. 2015 Jan; 61(1):141-52.
    View on PubMed
  3. Mechanisms of Liver Injury in Non-Alcoholic Steatohepatitis. Curr Hepatol Rep. 2014 Jun 1; 13(2):119-129.
    View on PubMed
  4. Circulating interleukin-8 levels explain breast cancer osteolysis in mice and humans. Bone. 2014 Apr; 61:176-85.
    View on PubMed
  5. Targeting of av integrin identifies a core molecular pathway that regulates fibrosis in several organs. Nat Med. 2013 Dec; 19(12):1617-24.
    View on PubMed
  6. A liver Hif-2a-Irs2 pathway sensitizes hepatic insulin signaling and is modulated by Vegf inhibition. Nat Med. 2013 Oct; 19(10):1331-7.
    View on PubMed
  7. Retinol binding protein 4 and fatty liver: A direct link? Hepatology. 2013 Aug; 58(2):477-9.
    View on PubMed
  8. Hepatic fibrosis: evaluation with semiquantitative contrast-enhanced CT. Radiology. 2013 Jan; 266(1):151-8.
    View on PubMed
  9. Insulin sensitivity and variability in hepatitis C virus infection using direct measurement. Dig Dis Sci. 2013 Apr; 58(4):1141-8.
    View on PubMed
  10. The basic helix-loop-helix transcription factor, heart and neural crest derivatives expressed transcript 2, marks hepatic stellate cells in zebrafish: analysis of stellate cell entry into the developing liver. Hepatology. 2012 Nov; 56(5):1958-70.
    View on PubMed
  11. Specific bile acids inhibit hepatic fatty acid uptake in mice. Hepatology. 2012 Oct; 56(4):1300-10.
    View on PubMed
  12. Impact of insulin resistance on HCV treatment response and impact of HCV treatment on insulin sensitivity using direct measurements of insulin action. Diabetes Care. 2012 May; 35(5):1090-4.
    View on PubMed
  13. Assessment of factors associated with pre-diabetes in HCV infection including direct and dynamic measurements of insulin action. J Viral Hepat. 2012 Jul; 19(7):480-7.
    View on PubMed
  14. Lipids in liver disease: looking beyond steatosis. Gastroenterology. 2012 Jan; 142(1):8-11.
    View on PubMed
  15. New insights from rodent models of fatty liver disease. Antioxid Redox Signal. 2011 Jul 15; 15(2):535-50.
    View on PubMed
  16. Stress signaling in the methionine-choline-deficient model of murine fatty liver disease. Gastroenterology. 2010 Nov; 139(5):1730-9, 1739.e1.
    View on PubMed
  17. Comparison of surrogate and direct measurement of insulin resistance in chronic hepatitis C virus infection: impact of obesity and ethnicity. Hepatology. 2010 Jul; 52(1):38-46.
    View on PubMed
  18. Computational experiments reveal plausible mechanisms for changing patterns of hepatic zonation of xenobiotic clearance and hepatotoxicity. J Theor Biol. 2010 Aug 21; 265(4):718-33.
    View on PubMed
  19. Dietary fructose exacerbates hepatocellular injury when incorporated into a methionine-choline-deficient diet. Liver Int. 2010 Sep; 30(8):1229-39.
    View on PubMed
  20. Trunk fat as a determinant of liver disease. Gastroenterology. 2010 Apr; 138(4):1244-6.
    View on PubMed

Go to UCSF Profiles, powered by CTSI